Megalencephaly: Classification, Genetic Causes, and Related Syndromes

Abstract

Megalencephaly is a developmental disorder due to an abnormal neuronal proliferation and migration during intrauterine or postnatal brain development that leads to cerebral overgrowth and neurological dysfunction. This cerebral overgrowth may affect the whole encephalon or only a region; when it involves one hemisphere it is referred to as hemimegalencephaly. Megalencephaly presents with a head circumference measurement of 2 standard deviations above the average measure for age. This group of disorders is clinically characterized by early onset and refractory to therapy epilepsy, neurodevelopmental disorders, behavioral problems, and autism spectrum disorder. Syndromic forms of megalencephaly should be considered when associated with other congenital abnormalities. Megalencephaly in fact could be associated with segmental overgrowth and cutaneous/vascular abnormalities (i.e., Proteus syndrome, CLOVES [congenital lipomatous overgrowth, vascular malformations, epidermal naevi, scoliosis, and/ or skeletal abnormalities] syndrome, Klippel-Trenaunay syndrome, megalencephaly-capillary malformation-polymicrogyria syndrome , megalencephaly-postaxial polydactyly-polymicrogyria-hydrocephalus syndrome, etc.) or generalized overgrowth (i.e., Weaver or Beckwith-Wiedemann syndrome) as well as with nanism in achondroplasia where megalencephaly is associated with disproportionate short stature, primary skeletal dysplasia, characteristic facies (prominent forehead, flat nasal bridge), narrow chest, and normal intelligence. It is possible to identify three main groups of disorders associated with megalencephaly: idiopathic or benign, metabolic, and anatomic. The idiopathic (benign) form indicates an abnormal increased head circumference in absence of neurological impairment, such as in benign familial megalencephaly. In metabolic megalencephaly (such as in organic acid disorders, metabolic leukoencephalopathies, or lysosomal diseases) there is an increase of different constituents that increase the size of the brain, whereas in the anatomical form there are underlying genetic causes. Neuroimaging is crucial for diagnosis, as it can reveal a generalized brain growth or a segmental one and possible specific frameworks associated. In all these conditions it is necessary to identify possible microdeletion-microduplication by chromosomal arrays.

Keywords

megalencephaly - hemimegalencephaly - macrocephaly - epilepsy - rehabilitation

^* The authors contributed equally to the article.

Publication History

Received: 05 December 2023

Accepted: 04 April 2024

Article published online:
11 May 2024

• References

• 1 DeMeyer W. Megalencephaly in children. Clinical syndromes, genetic patterns, and differential diagnosis from other causes of megalocephaly. Neurology 1972; 22 (06) 634-643
• 2 Barbagallo M, Ruggieri M, Incorpora G. et al. Infantile spasms in the setting of Sturge-Weber syndrome. Childs Nerv Syst 2009; 25 (01) 111-118
• 3 Winden KD, Yuskaitis CJ, Poduri A. Megalencephaly and macrocephaly. Semin Neurol 2015; 35 (03) 277-287
• 4 Falsaperla R, D'Angelo G, Praticò AD. et al. Ketogenic Diet for Infants with Epilepsy: A Literature Review. Epilepsy & Beavior; 2020. 112. 107361
• 5 Jaiswal V, Hanif M, Sarfraz Z. et al. Hemimegalencephaly: a rare congenital malformation of cortical development. Clin Case Rep 2021; 9 (12) e05238
• 6 Pavone P, Praticò AD, Falsaperla R. et al. Congenital generalized hypertrichosis: the skin as a clue to complex malformation syndromes. Ital J Pediatr 2015; 41: 55
• 7 Pavone P, Praticò AD, Rizzo R. et al. A clinical review on megalencephaly: a large brain as a possible sign of cerebral impairment. Medicine (Baltimore) 2017; 96 (26) e6814
• 8 Praticò AD, Pavone P, Scuderi MG. et al. Symptomatic hypocalcemia in an epileptic child treated with valproic acid plus lamotrigine: a case report. Cases J 2009; 2: 7394
• 9 Accogli A, Geraldo AF, Piccolo G. et al. Diagnostic approach to macrocephaly in children. Front Pediatr 2022; 9: 794069
• 10 Pavone V, Signorelli SS, Praticò AD. et al. Total hemi-overgrowth in pigmentary mosaicism of the (hypomelanosis of) Ito type: eight case reports. Medicine (Baltimore) 2016; 95 (10) e2705
• 11 Day RE, Schutt WH. Normal children with large heads–benign familial megalencephaly. Arch Dis Child 1979; 54 (07) 512-517
• 12 Pavone P, Falsaperla R, Ruggieri M. et al. Clinical course of N-methyl-D-aspartate receptor encephalitis and the effectiveness of cyclophosphamide treatment. J Pediatr Neurol 2017; 15: 84-49
• 13 Pirozzi F, Nelson B, Mirzaa G. From microcephaly to megalencephaly: determinants of brain size. Dialogues Clin Neurosci 2018; 20 (04) 267-282
• 14 Falsaperla R, Perciavalle V, Pavone P. et al. Unilateral eye blinking arising from the ictal ipsilateral occipital area. Clin EEG Neurosci 2016; 47 (03) 243-246
• 15 Mirzaa GM, Poduri A. Megalencephaly and hemimegalencephaly: breakthroughs in molecular etiology. Am J Med Genet C Semin Med Genet 2014; 166C [phone]
• 16 Pavone P, Falsaperla R, Ruggieri M, Praticò AD, Pavone L. West syndrome treatment: new roads for an old syndrome. Front Neurol 2013; 4: 113
• 17 Leibovitz Z, Lerman-Sagie T, Haddad L. Fetal brain development: regulating processes and related malformations. Life (Basel) 2022; 12 (06) 809
• 18 Ruggieri M, Praticò AD, Caltabiano R, Polizzi A. Rediagnosing one of Smith's patients (John McCann) with “neuromas tumours” (1849). Neurol Sci 2017; 38 (03) 493-499
• 19 Tatton-brown K, Bch BM, Cole TRP, Chb MB, Bch BM. Sotos syndrome summary genetic counseling suggestive findings. Gener Rev 2022; xx: 1-19
• 20 Palano GM, Praticò AD, Praticò ER. et al. Intossicazione accidentale da alcol etilico in un lattante di 30 giorni. Quadro clinico e follow-up neurologico. [Accidental ethyl alcohol intoxication in a 30-day-old infant. Clinical findings and neurological follow-up] Minerva Pediatr 2007; 59 (03) 275-279
• 21 Tatton-Brown K, Murray A, Hanks S. et al; Childhood Overgrowth Consortium. Weaver syndrome and EZH2 mutations: clarifying the clinical phenotype. Am J Med Genet A 2013; 161A (12) 2972-2980
• 22 Vitaliti G, Praticò AD, Cimino C. et al. Hepatitis B vaccine in celiac disease: yesterday, today and tomorrow. World J Gastroenterol 2013; 19 (06) 838-845
• 23 Tenorio J, Arias P, Martínez-Glez V. et al. Simpson-Golabi-Behmel syndrome types I and II. Orphanet J Rare Dis 2014; 9: 138
• 24 Leonardi S, Praticò AD, Lionetti E, Spina M, Vitaliti G, La Rosa M. Intramuscular vs intradermal route for hepatitis B booster vaccine in celiac children. World J Gastroenterol 2012; 18 (40) 5729-5733
• 25 Bouali H, Latrech H. Achondroplasia: current options and future perspective. Pediatr Endocrinol Rev 2015; 12 (04) 388-395
• 26 Vitaliti G, Cimino C, Coco A, Praticò AD, Lionetti E. The immunopathogenesis of cow's milk protein allergy (CMPA). Ital J Pediatr 2012; 38: 35
• 27 Ruggieri M, Polizzi A, Marceca GP, Catanzaro S, Praticò AD, Di Rocco C. Introduction to phacomatoses (neurocutaneous disorders) in childhood. Childs Nerv Syst 2020; 36 (10) 2229-2268
• 28 Fiumara A, Lanzafame G, Arena A. et al. COVID-19 pandemic outbreak and its psychological impact on patients with rare lysosomal diseases. J Clin Med 2020; 9 (09) 2716
• 29 Legius E, Messiaen L, Wolkenstein P. et al; International Consensus Group on Neurofibromatosis Diagnostic Criteria (I-NF-DC). Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genet Med 2021; 23 (08) 1506-1513
• 30 Praticò AD, Leonardi S. Immunotherapy for food allergies: a myth or a reality?. Immunotherapy 2015; 7 (02) 147-161
• 31 Northrup H, Aronow ME, Bebin EM. et al; International Tuberous Sclerosis Complex Consensus Group. Updated international tuberous sclerosis complex diagnostic criteria and surveillance and management recommendations. Pediatr Neurol 2021; 123: 50-66
• 32 Pratico AD, Salafia S, Barone P, La Rosa M, Leonardi S. Type II autoimmune hepatitis and small duct sclerosing cholangitis in a seven years old child: an overlap syndrome?. Hepat Mon 2013; 13 (12) e14452
• 33 Shiohama T, Fujii K, Miyashita T, Mizuochi H, Uchikawa H, Shimojo N. Brain morphology in children with nevoid basal cell carcinoma syndrome. Am J Med Genet A 2017; 173 (04) 946-952
• 34 Praticò AD, Ruggieri M. COVID-19 vaccination for children: may be necessary for the full eradication of the disease. Pediatr Res 2021; 90 (06) 1102-1103
• 35 Sarma K, Nayak MK, Mishra B, Gaikwad SB. Megalencephaly-capillary malformation-polymicrogyria syndrome (MCAP): a rare dynamic genetic disorder. Cureus 2022; 14 (05) e25123
• 36 Praticò AD, Polizzi A, Salafia R. et al. Megalencephaly capillary malformation syndrome. J Pediatr Neurol 2018; 16: 328-337
• 37 St John LJ, Rao N. Autism spectrum disorder in a child with megalencephaly-capillary malformation-polymicrogyria syndrome (MCAP). BMJ Case Rep 2021; 14 (12) e247034
• 38 Praticò AD, Mistrello G, La Rosa M. et al. Immunotherapy: a new horizon for egg allergy?. Expert Rev Clin Immunol 2014; 10 (05) 677-686
• 39 Mirzaa GM, Conway RL, Gripp KW. et al. Megalencephaly-capillary malformation (MCAP) and megalencephaly-polydactyly-polymicrogyria-hydrocephalus (MPPH) syndromes: two closely related disorders of brain overgrowth and abnormal brain and body morphogenesis. Am J Med Genet A 2012; 158A [phone]
• 40 Praticò AD. COVID-19 pandemic for pediatric health care: disadvantages and opportunities. Pediatr Res 2021; 89 (04) 709-710
• 41 Jaiswal V, Hanif M, Sarfraz Z. et al. Hemimegalencephaly: a rare congenital malformation of cortical development. Clin Case Rep 2021; 9 (12) e05238
• 42 Praticò AD, Falsaperla R, Comella M, Belfiore G, Polizzi A, Ruggieri M. Case report: a gain-of-function of hamartin may lead to a distinct “inverse TSC1-hamartin” phenotype characterized by reduced cell growth. Front Pediatr 2023; 11: 1101026
• 43 Pavone P, Polizzi A, Marino SD. et al. West syndrome: a comprehensive review. Neurol Sci 2020; 41 (12) 3547-3562
• 44 Kölker S, Christensen E, Leonard JV. et al. Diagnosis and management of glutaric aciduria type I–revised recommendations. J Inherit Metab Dis 2011; 34 (03) 677-694
• 45 Polizzi A, Finocchiaro M, Parano E, Pavone P, Musumeci S, Polizzi A. Recurrent peripheral neuropathy in a girl with celiac disease. J Neurol Neurosurg Psychiatry 2000; 68 (01) 104-105
• 46 Strauss KA, Puffenberger EG, Robinson DL, Morton DH. Type I glutaric aciduria, part 1: natural history of 77 patients. Am J Med Genet C Semin Med Genet 2003; 121C (01) 38-52
• 47 Polizzi A, Coghill S, McShane MA, Squier W. Acute ataxia complicating Langherans cell histiocytosis. Arch Dis Child 2002; 86 (02) 130-131
• 48 Cornelius LP, Raju V, Julin A. Pediatric glutaric aciduria type 1: 14 cases, diagnosis and management. Ann Indian Acad Neurol 2021; 24 (01) 22-26
• 49 Nicita F, Ruggieri M, Polizzi A. et al. Seizures and epilepsy in Sotos syndrome: analysis of 19 Caucasian patients with long-term follow-up. Epilepsia 2012; 53 (06) e102-e105
• 50 Renaud DL. Leukoencephalopathies associated with macrocephaly. Semin Neurol 2012; 32 (01) 34-41
• 51 Ruggieri M, Polizzi A. From Aldrovandi's “Homuncio” (1592) to Buffon's girl (1749) and the “Wart Man” of Tilesius (1793): antique illustrations of mosaicism in neurofibromatosis?. J Med Genet 2003; 40 (03) 227-232
• 52 Heringer J, Boy SPN, Ensenauer R. et al. Use of guidelines improves the neurological outcome in glutaric aciduria type I. Ann Neurol 2010; 68 (05) 743-752
• 53 Salpietro V, Mankad K, Kinali M. et al. Pediatric idiopathic intracranial hypertension and the underlying endocrine-metabolic dysfunction: a pilot study. J Pediatr Endocrinol Metab 2014; 27 (1-2): 107-115
• 54 Kolker S, Greenberg CR, Lindner M, Muller E, Naughten ER, Hoffmann GF. Emergency treatment in glutaryl-CoA dehydrogenase de¢ciency. J Inherit Metab Dis 2004; 27 (06) 893-902
• 55 Sorge G, Ruggieri M, Polizzi A, Scuderi A, Di Pietro M. SHORT syndrome: a new case with probable autosomal dominant inheritance. Am J Med Genet 1996; 61 (02) 178-181
• 56 Fine A, Schupack KM. Childhood neurologic conditions: neuroanatomic abnormalities. FP Essent 2022; 523: 27-42
• 57 Ruggieri M, Gabriele AL, Polizzi A. et al. Natural history of neurofibromatosis type 2 with onset before the age of 1 year. Neurogenetics 2013; 14 (02) 89-98
• 58 Jafari P, Braissant O, Bonafé L, Ballhausen D. The unsolved puzzle of neuropathogenesis in glutaric aciduria type I. Mol Genet Metab 2011; 104 (04) 425-437
• 59 Salpietro V, Phadke R, Saggar A. et al. Zellweger syndrome and secondary mitochondrial myopathy. Eur J Pediatr 2015; 174 (04) 557-563
• 60 Mühlhausen C, Hoffmann GF, Strauss KA. et al. Maintenance treatment of glutaryl-CoA dehydrogenase deficiency. J Inherit Metab Dis 2004; 27 (06) 885-892
• 61 Ruggieri M. Mosaic (segmental) neurofibromatosis type 1 (NF1) and type 2 (NF2): no longer neurofibromatosis type 5 (NF5). Am J Med Genet 2001; 101 (02) 178-180
• 62 Salpietro V, Polizzi A, Di Rosa G. et al. Adrenal disorders and the paediatric brain: pathophysiological considerations and clinical implications. Int J Endocrinol 2014; 2014: 282489
• 63 Nyhan WL, Shelton GD, Jakobs C. et al. D-2-hydroxyglutaric aciduria. J Child Neurol 1995; 10 (02) 137-142
• 64 Ruggieri M, Polizzi A. Segmental neurofibromatosis. J Neurosurg 2000; 93 (03) 530-532
• 65 Messing A. Alexander disease. Handb Clin Neurol 2018; 148: 693-700
• 66 Falsaperla R, Praticò AD, Ruggieri M. et al. Congenital muscular dystrophy: from muscle to brain. Ital J Pediatr 2016; 42 (01) 78
• 67 van der Knaap MS, Naidu S, Breiter SN. et al. Alexander disease: diagnosis with MR imaging. AJNR Am J Neuroradiol 2001; 22 (03) 541-552
• 68 Brismar J, Brismar G, Gascon G, Ozand P. Canavan disease: CT and MR imaging of the brain. AJNR Am J Neuroradiol 1990; 11 (04) 805-810
• 69 Bokhari MR, Samanta D, Bokhari SRA. Canavan Disease. July 3, 2023. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; ; January 2023
• 70 Israni AV, Mandal A. Canavan disease with typical brain MRI and MRS findings. Neurol India 2017; 65 (05) 1191-1192
• 71 Hamilton EMC, Tekturk P, Cialdella F. et al; MLC Research Group. Megalencephalic leukoencephalopathy with subcortical cysts: characterization of disease variants. Neurology 2018; 90 (16) e1395-e1403
• 72 Tan AP, Mankad K, Gonçalves FG, Talenti G, Alexia E. Macrocephaly: solving the diagnostic dilemma. In: Topics in Magnetic Resonance Imaging. Vol. 27. Lippincott Williams and Wilkins; Philadelphia (USA): 2018: 197-217
• 73 Bradbury AM, Bongarzone ER, Sands MS. Krabbe disease: new hope for an old disease. Neurosci Lett 2021; 752: 135841
• 74 Bugiani M, Vuong C, Breur M, van der Knaap MS. Vanishing white matter: a leukodystrophy due to astrocytic dysfunction. Brain Pathol 2018; 28 (03) 408-421
• 75 Michaud M, Belmatoug N, Catros F. et al. Mucopolysaccharidosis: a review [in French]. Rev Med Interne 2020; 41 (03) 180-188
• 76 Karimzadeh P, Jafari N, Nejad Biglari H. et al. GM2-gangliosidosis (Sandhoff and Tay Sachs disease): diagnosis and neuroimaging findings (an Iranian pediatric case series). Iran J Child Neurol 2014; 8 (03) 55-60
• 77 Filho JAF, Shapiro BE. Tay-Sachs disease. Arch Neurol 2004; 61: 1466-1468
• 78 Patterson MC. Gangliosidoses. Handb Clin Neurol 2013; 113: 1707-1708
• 79 Jayawant S, Halpin S, Wallace S. Menkes kinky hair disease: an unusual case. Eur J Paediatr Neurol 2000; 4 (03) 131-134
• 80 Dang LT, Vaid S, Lin G. et al. STRADA-mutant human cortical organoids model megalencephaly and exhibit delayed neuronal differentiation. Dev Neurobiol 2021; 81 (05) 696-709
• 81 Biesecker LG. The Greig cephalopolysyndactyly syndrome. Orphanet J Rare Dis 2008; 3 (01) 10
• 82 Marciniak C, McAllister P, Walker H. et al; International AbobotulinumtoxinA Adult Upper Limb Spasticity Study Group. Efficacy and safety of abobotulinumtoxinA (dysport) for the treatment of hemiparesis in adults with upper limb spasticity previously treated with botulinum toxin: subanalysis from a phase 3 randomized controlled trial. PM R 2017; 9 (12) 1181-1190
• 83 Vecchio M, Gracies JM, Panza F. et al. Change in coefficient of fatigability following rapid, repetitive movement training in post-stroke spastic paresis: a prospective open-label observational study. J Stroke Cerebrovasc Dis 2017; 26 (11) 2536-2540
• 84 Gracies JM, Jech R, Valkovic P. et al. When can maximal efficacy occur with repeat botulinum toxin injection in upper limb spastic paresis?. Brain Commun 2020; 3 (01) fcaa201